Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma

• DOI: 10.3389/fphar.2021.732912
• Publication Date: 2021-11-16T04:50:32Z
• Authors: Hongfu Cai; Baohua Xu; Na Li; Bin Zheng; Zhiwei Zheng; Maobai Liu
• Keywords: Pharmacology; 03 medical and health sciences; 0302 clinical medicine; camrelizumab; esophageal cancer; Therapeutics. Pharmacology; RM1-950; chemotherapy; cost-effectiveness; esophageal squamous cell carcinoma; 3. Good health

Background: This study aimed to analyze the cost effectiveness of camrelizumab in second-line treatment advanced or metastatic esophageal squamous cell carcinoma China. Methods: On basis ESCORT clinical trial, a partitioned survival model was constructed simulate patient’s lifetime quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratio (ICER). One-way sensitivity probability analyses were performed test stability model. Results: Treatment with added 0.36 QALYs resulted an $1,439.64 compared chemotherapy, which had ICER $3,999 per QALY gained. The far lower than threshold willingness pay for one time GDP capita Sensitivity analysis revealed that ICERs most sensitive drugs, but parameters did not have major effect on results Conclusion: Camrelizumab is likely be cost-effective option chemotherapy patients carcinoma. informs patient selection path development.